The Role of Biomarkers in Predicting Cardiovascular Events in Autoimmune Diseases: Insights into Early Detection and Risk Stratification
Main Article Content
Abstract
Autoimmune diseases (AIDs) are characterized by chronic inflammation and immune dysregulation, significantly increasing the risk of cardiovascular events (CVE). The identification and utilization of reliable biomarkers to predict CVE in patients with AIDs hold promise for improving early detection, risk stratification, and targeted intervention strategies. This article explores the current evidence supporting the role of biomarkers, including inflammatory mediators, endothelial dysfunction markers, autoantibodies, and novel genomic and proteomic signatures. Additionally, we discuss their clinical applicability, limitations, and integration into routine practice. Understanding the interplay between biomarkers and the pathophysiological mechanisms underlying cardiovascular complications in AIDs may pave the way for precision medicine approaches, optimizing outcomes in this vulnerable population.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. The global burden of cardiovascular diseases and risk: a compass for future health. Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA. J Am Coll Cardiol. 2022;80:2361–2371.
doi: 10.1016/j.jacc.2022.11.005.
II. Emerging biomarkers for the detection of cardiovascular diseases. Thupakula S, Nimmala SS, Ravula H, Chekuri S, Padiya R. Egypt Heart J. 2022;74:77. doi: 10.1186/s43044-022-00317-2.
III. Global trends and regional differences in incidence and mortality of cardiovascular disease, 1990-2019: findings from 2019 global burden of disease study. Li Y, Cao GY, Jing WZ, Liu J, Liu M. Eur J Prev Cardiol. 2023;30:276–286.
doi: 10.1093/eurjpc/zwac285
IV. Epidemiology of coronary heart disease and acute coronary syndrome. Sanchis-Gomar F, Perez-Quilis C, Leischik R, Lucia A. Ann Transl Med. 2016;4:256. doi: 10.21037/atm.2016.06.33.
V. Circulating biomarkers for cardiovascular disease risk prediction in patients with cardiovascular disease. Wong YK, Tse HF. Front Cardiovasc Med. 2021;8:713191. doi: 10.3389/fcvm.2021.713191.
VI. The Framingham Risk Score: an appraisal of its benefits and limitations. Hemann BA, Bimson WF, Taylor AJ. Am Heart Hosp J. 2007;5:91–96.
doi: 10.1111/j.1541-9215.2007.06350.x.
VII. .Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association. Chow SL, Maisel AS, Anand I, et al. Circulation. 2017;135:0–91.
doi: 10.1161/CIR.0000000000000490.
VIII. Biomarkers in cardiovascular disease: Statistical assessment and section on key novel heart failure biomarkers. Dhingra R, Vasan RS. Trends Cardiovasc Med. 2017;27:123–133.
doi: 10.1016/j.tcm.2016.07.005.
IX. Dasgupta A, Wahed A. Elsevier. 2 . Science Direct: Elsevier; 2021. Cardiac markers. Clinical Chemistry, Immunology and Laboratory Quality Control ; pp. 149–171
X. Novel biomarkers for cardiovascular risk prediction. Wang J, Tan GJ, Han LN, Bai YY, He M, Liu HB. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5409355/pdf/jgc-14-02-135.pdf. J Geriatr Cardiol. 2017;14:135–150.
doi:10.11909/j.issn.1671-5411.2017.02.008.
XI. Hospital laboratory reporting may be a barrier to detection of 'microsize' myocardial infarction in the US: an observational study. Safford MM, Parmar G, Barasch CS, et al. BMC Health Serv Res. 2013;13:162. doi: 10.1186/1472-6963-13-162.
XII. Third universal definition of myocardial infarction. Thygesen K, Alpert JS, Jaffe AS, et al. Eur Heart J. 2012;33:2551–2567.
XIII. Preparing the United States for high-sensitivity cardiac troponin assays. Korley FK, Jaffe AS. J Am Coll Cardiol. 2013;61:1753–1758.
doi: 10.1016/j.jacc.2012.09.069.
XIV. Fatty acid-binding proteins as plasma markers of tissue injury. Pelsers MM, Hermens WT, Glatz JF. Clin Chim Acta. 2005;352:15–35.
doi: 10.1016/j.cccn.2004.09.001.
XV. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Devaraj S, Xu DY, Jialal I. Circulation. 2003;107:398–404.
doi: 10.1161/01.cir.0000052617.91920.fd.
XVI. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. Vlachopoulos C, Xaplanteris P, Aboyans V, et al. Atherosclerosis. 2015;241:507–532. doi: 10.1016/j.atherosclerosis.2015.05.007.
XVII. Macrophage inhibitory cytokine-1 (MIC-1/GDF15): a new marker of all-cause mortality. Wiklund FE, Bennet AM, Magnusson PK, et al. Aging Cell. 2010;9:1057–1064.
doi: 10.1111/j.1474-9726.2010.00629.x.
XVIII. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. Danesh J, Lewington S, Thompson SG, et al. JAMA. 2005;294:1799–1809.
doi: 10.1001/jama.294.14.1799.